$EDSA News
Last published 2d ago
- 2d agoEDSAEdesa Biotech Announces Agreement with KYORIN Pharmaceutical to Develop and Commercialize Paridiprubart in JapanGlobeNewswireDeal valued at more than $140 million in upfront and potential milestone payments, plus double-digit royalties.Kyorin obtains exclusive rights to develop and commercialize paridiprubart, an anti-TLR4 monoclonal
- 2d agoEDSAEdesa Biotech Announces Agreement with KYORIN Pharmaceutical to Develop and Commercialize Paridiprubart in JapanGlobeNewswireTORONTO and TOKYO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, and KYORIN Pharmaceutical Co., Ltd. (TSE: 4569), a leading Japanese pharmaceutical company, today announced that they have entered into an exclusive collaboration and license agreement ...
- 1w agoEDSAEdesa Biotech to Present at Guggenheim Healthcare Innovation ConferenceGlobeNewswireTORONTO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today
- 3w agoEDSAEdesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo StudyGlobeNewswireEnables expansion of ongoing vitiligo clinical study to U.S. investigational sitesTopline data anticipated Q4 2027 TORONTO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage
- 2mo agoEDSAEdesa Biotech Announces Pricing of $25.0 Million Public OfferingGlobeNewswireTORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA) (the "Company" or "Edesa"), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for
- 2mo agoEDSAEdesa Biotech Announces Proposed Public OfferingGlobeNewswireTORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA) (the "Company" or "Edesa"), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for
- 3mo agoEDSAEdesa Biotech Reports Fiscal 3rd Quarter 2026 ResultsGlobeNewswireTORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today
- 5mo agoEDSAEdesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused InvestorsGlobeNewswireTORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA) (the "Company" or "Edesa"), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for
- 5mo agoEDSAEdesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney InjuryGlobeNewswireAnalyses demonstrate consistent positive signals across endpoints in AKI patientsFindings derived from post hoc analysis of 101 patients also experiencing respiratory distressNew data and analysis to be presented today
- 5mo agoEDSAEdesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology ConferenceGlobeNewswireOral presentation at ERA Congress, the flagship European nephrology meetingCompany expects to present additional data TORONTO, May 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage
- 6mo agoEDSAEdesa Biotech Reports Fiscal 2nd Quarter 2026 ResultsGlobeNewswireTORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported
- 7mo agoEDSAEdesa Biotech Invited for Oral Showcase at Respiratory Innovation SummitGlobeNewswireTORONTO, March 31, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today
- 7mo agoEDSAEdesa Biotech Advances Vitiligo Program for Planned Mid-2026 EnrollmentGlobeNewswireTORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today
- 8mo agoEDSAEdesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart StudyGlobeNewswireResults in a population of 278 patients affirm statistically significant mortality reductionsBenefits observed across severity groups and in subjects with serious comorbiditiesCompany files provisional patent
- 9mo agoEDSAEdesa Biotech Reports Fiscal 1st Quarter 2026 ResultsGlobeNewswireTORONTO, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported
- 11mo agoEDSAEdesa Biotech Reports Fiscal Year 2025 ResultsGlobeNewswireTORONTO, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported
- 1y agoEDSAEdesa Biotech Announces Upcoming Conference ScheduleGlobeNewswireTORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced
- 1y agoEDSAEdesa Biotech Reports Positive Results in Phase 3 Respiratory StudyGlobeNewswireStudy met primary and secondary endpointsParidiprubart demonstrated a relative reduction in the risk of death of 25%Treatment provided patients with clinically meaningful improvement in survival and recovery
- 1y agoEDSAEdesa Biotech Reports Fiscal 3rd Quarter 2025 ResultsGlobeNewswireTORONTO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported
- 1y agoEDSAEdesa Biotech Reports Fiscal 2nd Quarter 2025 ResultsGlobeNewswireTORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported
- 1y agoEDSAEdesa Biotech to Participate in Bloom Burton Healthcare Investor ConferenceGlobeNewswireTORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced
- 1y agoEDSAEdesa Biotech Announces Chief Financial Officer TransitionGlobeNewswireTORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today
- 1y agoEDSAEdesa Biotech Reports Fiscal 1st Quarter 2025 ResultsGlobeNewswireTORONTO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported
- 1y agoEDSAEdesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq RulesGlobeNewswireFinancing led by Velan Capital with participation from new and existing healthcare-focused institutional investors and insidersCapital raise to fund Edesa's CXCL10 antibody program through the end of fiscal 2026
- 1y agoEDSAEdesa Biotech Reports Fiscal Year 2024 ResultsGlobeNewswireTORONTO, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported
- 2y agoEDSAEdesa Biotech's Founder Makes Strategic Investment in the CompanyGlobeNewswireTORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today
- 2y agoEDSAEdesa Biotech Announces Upcoming Conference ScheduleGlobeNewswireTORONTO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced
- 2y agoEDSAEdesa Biotech Reports Fiscal 3rd Quarter 2024 ResultsGlobeNewswireTORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported
- 2y agoEDSABARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDSACCESS NewswireThis Phase 2 clinical study will evaluate paridiprubart in hospitalized patients with acute respiratory distress syndrome due to a variety of causes.This BARDA-funded project is expected to complement
- 2y agoEDSAEdesa Biotech Reports Fiscal 2nd Quarter 2024 ResultsACCESS NewswireTORONTO, ON / ACCESSWIRE / May 10, 2024 / Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported
- 2y agoEDSAEdesa Biotech to Participate in Bloom Burton Healthcare Investor ConferenceACCESS NewswireTORONTO, ON / ACCESSWIRE / April 11, 2024 / Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today
- 2y agoEDSAEdesa Biotech to Participate in Upcoming Investor ConferencesACCESS NewswireTORONTO, ON / ACCESSWIRE / April 2, 2024 / Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today
- 2y agoEDSAEdesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory ConferenceACCESS NewswireTORONTO, ON / ACCESSWIRE / March 21, 2024 / Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today
- 2y agoEDSAEdesa Biotech to Participate in Barclays Global Healthcare ConferenceACCESS NewswireTORONTO, ON / ACCESSWIRE / March 7, 2024 / Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today
- 2y agoEDSAEdesa Biotech to Participate in Upcoming Dermatology MeetingsACCESS NewswireTORONTO, ON / ACCESSWIRE / March 4, 2024 / Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today
- 2y agoEDSAEdesa Biotech Reports Fiscal 1st Quarter 2024 ResultsACCESS NewswireTORONTO, ON / ACCESSWIRE / February 9, 2024 / Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today
- 2y agoEDSAEdesa Biotech to Participate in Dermatology Summit and JP Morgan WeekACCESS NewswireTORONTO, ON / ACCESSWIRE / January 4, 2024 / Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced
- 2y agoEDSAEdesa Biotech Reports Fiscal Year 2023 ResultsACCESS NewswireTORONTO, ON / ACCESSWIRE / December 15, 2023 / Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today
- 2y agoEDSAEdesa Biotech Reports Final Phase 2b Results for Dermatitis StudyACCESS Newswire1.0% Formulation Reached Primary Endpoint with Statistical SignificanceFull Analysis Identified Additional Efficacy SignalsTORONTO, ON / ACCESSWIRE / November 20, 2023 / Edesa Biotech, Inc. , a
- 3y agoEDSAEdesa Biotech to Present at Dermatology Drug Development SummitACCESS NewswireTORONTO, ON / ACCESSWIRE / October 26, 2023 / Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr. Par Nijhawan,
- 3y agoEDSARegulators Approve Updated Phase 3 Trial Design for Edesa Biotech's ARDS DrugACCESS NewswireTORONTO, ON / ACCESSWIRE / October 25, 2023 / Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that Health Canada has
- 3y agoEDSAEdesa Biotech Secures $10 Million Credit Facility with Company FounderACCESS NewswireRevolving Line of Credit to Support Completion of Government-Funded ARDS StudyTORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. , a
- 3y agoEDSAEdesa Biotech to Receive Up To C$23 Million in Funding from Federal GovernmentACCESS NewswireTORONTO, ON / ACCESSWIRE / October 12, 2023 / Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, has secured a commitment of up to C$23
- 3y agoEDSAEdesa Biotech Announces One-for-Seven Reverse Share SplitACCESS NewswireTORONTO, ON / ACCESSWIRE / October 10, 2023 / Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on inflammatory and immune-related
- 3y agoEDSAEdesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug CandidateACCESS NewswireCompany's host-directed therapeutic, EB05 , demonstrated a statistically significant mortality reduction among critically ill patients with severe respiratory diseaseTORONTO, ON / ACCESSWIRE / September
- 3y agoEDSAEdesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other PathogensACCESS NewswirePositive Findings Support Potential Expanded Uses for ParidiprubartTORONTO, ON / ACCESSWIRE / June 28, 2023 / Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on inflammatory and
- 3y agoEDSAEdesa Biotech Appoints Biotech Deal Veteran to CFO RoleACCESS NewswireTORONTO, ON / ACCESSWIRE / June 27, 2023 / Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company's board of
- 3y agoEDSAEdesa Biotech Reports Fiscal 2nd Quarter 2023 ResultsACCESS NewswireTORONTO, ON / ACCESSWIRE / May 11, 2023 / Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three
- 3y agoEDSAEdesa Biotech to Participate in Swiss Biotech DayACCESS NewswireTORONTO, ON / ACCESSWIRE / April 20, 2023 / Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that the company will join a
- 3y agoEDSAThe WHO and USAN Adopt Generic Name for Edesa's ARDS Drug CandidateACCESS NewswireInternational name assignment is a key step in Edesa's development and commercialization plansTORONTO, ON / ACCESSWIRE / April 4, 2023 / Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company